ProMetic Life Sciences’ (PLI) Outperform Rating Reaffirmed at Scotiabank

Short resume:

news
90%
stock
80%
reaffirmed
80%
outperform
70%
ProMetic Life Sciences' (PLI) Outperform Rating Reaffirmed at Scotiabank

ProMetic Life Sciences logo ProMetic Life Sciences Inc. (TSE:PLI)’s stock had its “outperform” rating reaffirmed by stock analysts at Scotiabank in a note issued to investors on Tuesday.
Source Community Financial News
Read More…

More News


Be the first to comment

Leave a Reply

Your email address will not be published.


*